In this webinar, we discussed how to interpret your pathology report. We covered interpretation of all parts of a pathology report, beginning with understanding the final diagnosis and diagnostic comment.
With the advent of Imatinib, tremendous progress has been made in the treatment of patients with GIST.
A new blood testing technology may lead to major changes in treatment of Gastrointestinal Stromal Tumors. In a study presented in April by Dr. George Demetri of the Dana-Farber Cancer Institute at the American Association for Cancer Research annual meeting, the blood test was shown to be more effective than traditional biopsies in identifying secondary mutations in GIST.
By Drs. Sebastian Bauer, West German Cancer Center, University of Essen, Germany and Jonathan Fletcher, Brigham & Women’s Hospital, Harvard University, LRG Research Team Researchers talk plainly about microGISTs, how this cancer develops and what all [...]
Written by Jennifer Wright April, 2011 - This article is a summary of “Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations” in the Proceedings of the National Academy of Sciences [...]
UPDATE - January 6th, 2011 by Jerry Call, LRG Science Coordinator The first ever clinical trial specifically for the PDGFRA D842V mutation has been announced by Arog pharmaceuticals. The phase II trial is scheduled [...]
1. Agaram NP, Besmer P, Wong GC, Guo T, Socci ND, Maki RG, DeSantis D, Brennan MF, Singer S, DeMatteo RP, Antonescu CR: Pathologic and Molecular Heterogeneity in Imatinib-Stable or Imatinib-Responsive Gastrointestinal Stromal Tumors. [...]
Sept, 2007 - A diverse group of researchers has found the genetic defects that cause a rare type of familial GIST called “Carney-Stratakis syndrome”. This syndrome has some similarities to Carney’s Triad but it [...]
This is part one of a two-part series on “KIT and PDGFRA kinase mutations in GIST: from A to Z”. In this newsletter, Dr. Heinrich will provide a background on the role of kinase mutations in GIST, focusing largely on the biological and clinical implications of these mutations. In part two (which will be featured in the July 2007 edition of the newsletter, following the special “Five-year anniversary” edition),
This is the second of a two-part series on KIT and PDGFRA mutations in GISTs, written collaboratively by Drs. Michael Heinrich and Christopher Corless, LRG research team members. Please refer to the May issue of our newsletter for the first part titled, “KIT & PDGFRA mutations in GIST: A to Z” by Dr. Heinrich.